Epithelioid glioblastoma

Changed by Frank Gaillard, 14 Nov 2021

Updates to Article Attributes

Body was changed:

Epithelioid glioblastoma is a classic variant of glioblastoma (along with gliosarcoma and giant cell glioblastoma) only recently added to recognised in the current (2021) WHO classification of CNS tumours as part of the 2016 update 14

Terminology

Whether or not epithelioid glioblastomas are distinct from rhabdoid glioblastomas is at present unclear, however, the latter term should be avoided and is not recognised in the current WHO classification 2,3

It is important to note that true epithelial differentiation of glioblastomas (typically squamous) is very rarely seen in adults but is distinct from epithelioid glioblastoma 2

Epidemiology

Unlike run-of-the-mill glioblastomas that are usually encountered in older adults, epithelioid glioblastomas have a predilection for young adults and children 1,3

Pathology

Epithelioid glioblastoma are WHO grade IV4 tumours 3. Interestingly, they sometimes co-exist with pleomorphic xanthoastrocytomas, however, their exact relationship is at present unclear 3

Microscopic appearance

These tumours are heterogeneous with large epithelioid cells that have abundant eosinophilic cytoplasm, vesicular chromatin, and prominent nucleoli. These cells are reminiscent of melanoma cells. Rhabdoid cells are also sometimes encountered 1.

Immunophenotype

Immunohistochemistry demonstrates a mixture of astrocytic and epithelial markers 3

Genetics

Approximately 50% of cases of epithelioid glioblastoma have BRAF V600E mutations 1-3

Radiographic features

Epithelioid glioblastomas most frequently present as diencephalic or less frequently superficial cerebral hemispheric masses 1,2. Haemorrhage and leptomeningeal seeding are probably fairly common at the time of diagnosis 2

These tumours are indistinguishable for glioblastoma on imaging, with enhancement, necrosis and diffusion restriction present in the vast majority of tumours 2

Treatment and prognosis

Epithelioid glioblastomas are aggressive tumours with poor prognosis, even worse than ordinary glioblastomas 3. In one series the median survival was only 169 days 2

These tumours also sometimes demonstrate systemic metastases, a very uncommon occurrence for other primary brain tumours 2

Differential diagnosis

In children the main differential is atypical teratoid / rhabdoid/rhabdoid tumour (AT/RT), distinguished by universal lack of INI1 expression in AT/RT 2

  • -<p><strong>Epithelioid glioblastoma </strong>is a variant of <a href="/articles/glioblastoma">glioblastoma</a> (along with <a href="/articles/gliosarcoma">gliosarcoma</a> and <a href="/articles/giant-cell-glioblastoma">giant cell glioblastoma</a>) only recently added to the <a href="/articles/who-classification-of-cns-tumours-1">WHO classification of CNS tumours</a> as part of the 2016 update <sup>1</sup>. </p><h4>Terminology</h4><p>Whether or not epithelioid glioblastomas are distinct from<strong> rhabdoid glioblastomas </strong>is at present unclear, however, the latter term should be avoided and is not recognised in the current WHO classification <sup>2,3</sup>. </p><p>It is important to note that true epithelial differentiation of glioblastomas (typically squamous) is very rarely seen in adults but is distinct from epithelioid glioblastoma <sup>2</sup>. </p><h4>Epidemiology</h4><p>Unlike run-of-the-mill glioblastomas that are usually encountered in older adults, epithelioid glioblastomas have a predilection for young adults and children <sup>1,3</sup>. </p><h4>Pathology</h4><p>Epithelioid glioblastoma are WHO grade IV tumours <sup>3</sup>. Interestingly, they sometimes co-exist with <a href="/articles/pleomorphic-xanthoastrocytoma">pleomorphic xanthoastrocytomas</a>, however, their exact relationship is at present unclear <sup>3</sup>. </p><h5>Microscopic appearance</h5><p>These tumours are heterogeneous with large epithelioid cells that have abundant eosinophilic cytoplasm, vesicular chromatin, and prominent nucleoli. These cells are reminiscent of melanoma cells. Rhabdoid cells are also sometimes encountered <sup>1</sup>.</p><h5>Immunophenotype</h5><p><a href="/articles/immunohistochemistry">Immunohistochemistry</a> demonstrates a mixture of astrocytic and epithelial markers <sup>3</sup>: </p><ul>
  • +<p><strong>Epithelioid glioblastoma </strong>is a classic variant of <a href="/articles/glioblastoma-idh-wildtype">glioblastoma</a> (along with <a href="/articles/gliosarcoma">gliosarcoma</a> and <a href="/articles/giant-cell-glioblastoma">giant cell glioblastoma</a>) recognised in the current (2021) <a href="/articles/who-classification-of-cns-tumours-1">WHO classification of CNS tumours</a> <sup>4</sup>. </p><h4>Terminology</h4><p>Whether or not epithelioid glioblastomas are distinct from<strong> rhabdoid glioblastomas </strong>is at present unclear, however, the latter term should be avoided and is not recognised in the current WHO classification <sup>2,3</sup>. </p><p>It is important to note that true epithelial differentiation of glioblastomas (typically squamous) is very rarely seen in adults but is distinct from epithelioid glioblastoma <sup>2</sup>. </p><h4>Epidemiology</h4><p>Unlike run-of-the-mill glioblastomas that are usually encountered in older adults, epithelioid glioblastomas have a predilection for young adults and children <sup>1,3</sup>. </p><h4>Pathology</h4><p>Epithelioid glioblastoma are WHO grade 4 tumours <sup>3</sup>. Interestingly, they sometimes co-exist with <a href="/articles/pleomorphic-xanthoastrocytoma">pleomorphic xanthoastrocytomas</a>, however, their exact relationship is at present unclear <sup>3</sup>. </p><h5>Microscopic appearance</h5><p>These tumours are heterogeneous with large epithelioid cells that have abundant eosinophilic cytoplasm, vesicular chromatin, and prominent nucleoli. These cells are reminiscent of melanoma cells. Rhabdoid cells are also sometimes encountered <sup>1</sup>.</p><h5>Immunophenotype</h5><p><a href="/articles/immunohistochemistry">Immunohistochemistry</a> demonstrates a mixture of astrocytic and epithelial markers <sup>3</sup>: </p><ul>
  • -</ul><h5>Genetics</h5><p>Approximately 50% of cases of epithelioid glioblastoma have <a title="BRAF" href="/articles/braf-1">BRAF V600E mutations</a> <sup>1-3</sup>. </p><h4>Radiographic features</h4><p>Epithelioid glioblastomas most frequently present as diencephalic or less frequently superficial cerebral hemispheric masses <sup>1,2</sup>. Haemorrhage and leptomeningeal seeding are probably fairly common at the time of diagnosis <sup>2</sup>. </p><p>These tumours are indistinguishable for glioblastoma on imaging, with enhancement, necrosis and diffusion restriction present in the vast majority of tumours <sup>2</sup>. </p><h4>Treatment and prognosis</h4><p>Epithelioid glioblastomas are aggressive tumours with poor prognosis, even worse than ordinary <a href="/articles/glioblastoma">glioblastomas</a> <sup>3</sup>. In one series the median survival was only 169 days <sup>2</sup>. </p><p>These tumours also sometimes demonstrate systemic metastases, a very uncommon occurrence for other primary brain tumours <sup>2</sup>. </p><h4>Differential diagnosis</h4><p>In children the main differential is <a href="/articles/atypical-teratoidrhabdoid-tumour">atypical teratoid / rhabdoid tumour</a> (AT/RT), distinguished by universal lack of INI1 expression in AT/RT <sup>2</sup>. </p>
  • +</ul><h5>Genetics</h5><p>Approximately 50% of cases of epithelioid glioblastoma have <a href="/articles/braf-1">BRAF V600E mutations</a> <sup>1-3</sup>. </p><h4>Radiographic features</h4><p>Epithelioid glioblastomas most frequently present as diencephalic or less frequently superficial cerebral hemispheric masses <sup>1,2</sup>. Haemorrhage and leptomeningeal seeding are probably fairly common at the time of diagnosis <sup>2</sup>. </p><p>These tumours are indistinguishable for glioblastoma on imaging, with enhancement, necrosis and diffusion restriction present in the vast majority of tumours <sup>2</sup>. </p><h4>Treatment and prognosis</h4><p>Epithelioid glioblastomas are aggressive tumours with poor prognosis, even worse than ordinary <a href="/articles/glioblastoma">glioblastomas</a> <sup>3</sup>. In one series the median survival was only 169 days <sup>2</sup>. </p><p>These tumours also sometimes demonstrate systemic metastases, a very uncommon occurrence for other primary brain tumours <sup>2</sup>. </p><h4>Differential diagnosis</h4><p>In children the main differential is <a href="/articles/atypical-teratoidrhabdoid-tumour">atypical teratoid/rhabdoid tumour</a> (AT/RT), distinguished by universal lack of INI1 expression in AT/RT <sup>2</sup>. </p>

References changed:

  • 2. Broniscer A, Tatevossian R, Sabin N et al. Clinical, Radiological, Histological and Molecular Characteristics of Paediatric Epithelioid Glioblastoma. Neuropathol Appl Neurobiol. 2014;40(3):327-36. <a href="https://doi.org/10.1111/nan.12093">doi:10.1111/nan.12093</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/24127995">Pubmed</a>
  • 3. Louis D, Ohgaki H, Wiestler O et al. The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol. 2007;114(2):97-109. <a href="https://doi.org/10.1007/s00401-007-0243-4">doi:10.1007/s00401-007-0243-4</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/17618441">Pubmed</a>
  • 4. Louis DN, Giannini C, Perry A, Reifenberger G, et al. Glioblastoma. In: WHO Classification of Tumours Editorial Board. Central nervous system tumours. Lyon (France): International Agency for Research on Cancer; 2021. (WHO classification of tumours series, 5th ed.; vol. 6). <a href="https://publications.iarc.fr/601.">https://publications.iarc.fr/601</a>
  • 2. Broniscer A, Tatevossian RG, Sabin ND et-al. Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma. Neuropathol. Appl. Neurobiol. 2014;40 (3): 327-36. <a href="http://dx.doi.org/10.1111/nan.12093">doi:10.1111/nan.12093</a> - <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4042629">Free text at pubmed</a> - <a href="http://www.ncbi.nlm.nih.gov/pubmed/24127995">Pubmed citation</a><span class="auto"></span>
  • 3. Louis DN, Ohgaki H, Wiestler OD et-al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114 (2): 97-109. <a href="http://link.springer.com/article/10.1007/s00401-007-0243-4/fulltext.html">Acta Neuropathol. (full text)</a> - <a href="http://dx.doi.org/10.1007/s00401-007-0243-4">doi:10.1007/s00401-007-0243-4</a> - <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1929165">Free text at pubmed</a> - <a href="http://www.ncbi.nlm.nih.gov/pubmed/17618441">Pubmed citation</a><span class="ref_v3"></span>

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.